loading page

Liver and kidney function in patients with Covid-19 treated with remdesivir
  • +2
  • Sylvia van Laar,
  • M De Boer,
  • Kim Gombert-Handoko,
  • HJ Guchelaar,
  • Juliette Zwaveling
Sylvia van Laar
Leiden University Medical Center
Author Profile
M De Boer
Leiden University Medical Center
Author Profile
Kim Gombert-Handoko
Leiden University Medical Center
Author Profile
HJ Guchelaar
Leiden University Medical Center
Author Profile
Juliette Zwaveling
Leiden University Medical Center
Author Profile

Abstract

For the treatment of Covid-19 patients with remdesivir, poor renal- and liver function were both exclusion criteria in randomized clinical trials (RCTs) and contra-indication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal- and liver functions of covid-19 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met RCT exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate larger than 10 ml/min/1.73m2. Also, 25% and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, contra-indications based on kidney- and liver function should not be absolute for remdesivir treatment in patients with Covid-19 if these functions are monitored regularly.

Peer review status:UNDER REVIEW

11 Jan 2021Submitted to British Journal of Clinical Pharmacology
13 Jan 2021Assigned to Editor
13 Jan 2021Submission Checks Completed
14 Jan 2021Reviewer(s) Assigned